Effects of testosterone administration on fat distribution, insulin sensitivity, and atherosclerosis progression

Clinical Infectious Diseases

Volumn 37, Issue SUPPL. 2, 2003, Pages

  Bhasin, Shalender ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BLOOD CLOTTING FACTOR; FIBRINOLYTIC FACTOR; GLUCOSE; GONADORELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; TESTOSTERONE; TESTOSTERONE ENANTATE; BIOLOGICAL MARKER;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHLETE; BODY COMPOSITION; BODY FAT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY RISK; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; EXPERIMENTAL MODEL; HEART DISEASE; HORMONE DEFICIENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; MUSCLE FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SUPPLEMENTATION; TESTOSTERONE BLOOD LEVEL; ADIPOSE TISSUE; ANIMAL; ARTERIOSCLEROSIS; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; HIV ASSOCIATED LIPODYSTROPHY; INSULIN RESISTANCE; MALE; METABOLISM; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; TESTOSTERONE;

EID: 0042262053     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375878     Document Type: Review

References (76)

1. Rolf C, Nieschlag E. Potential adverse effects of long-term testosterone therapy. Baillieres Clin Endocrinol Metab 1998; 12:521-34.
2. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125:1-13.
3. Hurley BF, Seals DR, Hagberg JM, et al. High-density-lipoprotein cholesterol in bodybuilders v powerlifters: negative effects of androgen use. JAMA 1984; 252:507-13.
4. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261:1165-8.
5. Crist DM, Peake GT, Stackpole PJ. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Clin Exp Pharmacol Physiol 1986; 13:513-8.
6. Taggart HM, Applebaum-Bowden D, Haffner S, et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism 1982; 31:1147-52.
7. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996; 335:1-7.
8. Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82:1661-7.
9. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:2647-53.
10. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966-72.
11. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75:1092-8.
12. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2:675-82.
13. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39:897-901.
14. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men: a prospective population-based study. Circulation 1988; 78:539-45.
15. Matin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16:991-997.
16. Rebuffe-Scrive M, Matin P, Bjorntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes Relat Metab Disord 1991; 15:791-5.
17. Matin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992; 1:329-36.
18. Arver SA, Sinha-Hikim I, Beall G, Shen R, Guerrero M, Bhasin S. Serum dihydrotestosterone and testosterone levels in human immunodeficiency virus-infected men with and without weight loss. J Androl 1999; 20:611-8.
19. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84:611-5.
20. Dobs AS, Few WL, Blackman MR, Harman SM, Hoover DR, Graham NMH. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab 1996; 81:4108-12.
21. Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in HIV wasting syndrome. J Acquit Immune Defic Retrovirol 1994; 7:46-51.
22. Croxon TC, Chapman WE, Miller LK, Levitt CD, Senie R, Zumoff B. Changes in the hypothalamic pituitary-gonadal axis in human immunodeficiency virus-infected hypogonadal men. J Clin Endocrinol Metab 1989; 68:317-21.
23. DePaepe ME, Vuletin JC, Lee MH, Rojas-Corona RR, Waxman M. Testicular atrophy in homosexual AIDS patients. Hum Pathol 1989; 20:572-8.
24. Laudet A, Blum L, Guechot J, et al. Changes in systematic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationship with CD4 counts. Eur J Endocrinol 1995; 133:418-24.
25. Meremich JA, McDermott MT, Asp AA, Harrison SM, Kidd GS. Evidence of endocrine involvement early in the course of human immunodeficiency virus infection. J Clin Endocrinol Metab 1990; 70:566-71.
26. Raffi F, Brisseau J-M, Planchon B, Remi JP, Barrier JH, Grolleau J-Y. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991; 5:729-33.
27. Salehian B, Jacobson D, Grafe M, McCutchan A, Swerdloff R. Pituitary-testicular axin during HIV infection: a prospective study [abstract 9]. In: Programs and abstracts of the 18th annual meeting of the American Society of Andrology (Tampa). Lawrence, KS: Allen Press, 1993.
28. Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31:1240-4.
29. Casaburi R, Goren S, Bhasin S. Substantial prevalence of low anabolic hormone levels in COPD patients undergoing rehabilitation. Am J Respir Crit Care Med 1996; 153:A128.
30. Handelsman DJ, Dong Q. Hypothalamic-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am 1993; 22:145-61.
31. Singh AB, Norris K, Modi N, et al. Pharmacokinetics ofa transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 2001; 86:2437-45.
32. Tsitsouras PD, Kowatch Ma, Briefel GR, et al. in vivo pretreatment with human chorionic gonadotropin fails to reverse the dysfunction of isolated Leydig cells from chronically uremic rats. Biol Reprod 1985; 33:781-5.
33. Wheatley T, Clark PM, Clark JD, Raggat PR, Evans D, Holder R. Pulsatility of luteinizing hormone in men with chronic renal failure: abnormal rather than absent. BMJ 1987;294:482.
34. Wibullaksanakul S, Handelsman DJ. Regulation of hypothalamic gonadotropin-releasing hormone secretion in experimental uremia: in vitro studies. Neuroendocrinology 1991; 54:353-8.
35. Veldhius DJ, Wilkowski MJ, Zwart AD, et al. Evidence for attenuation of hypothalamic gonadotropin releasing hormone (GnRH) impulse strength with preservation of GnRH pulse frequency in men with chronic renal failure. J Clin Endocrinol Metab 1993; 76:648-54.
36. Hasegawa K, Matsushita Y, Hirai K, et al. Abnormal response of luteinizing hormone, follicle stimulating hormone and testosterone to luteinizing hormone releasing hormone in chronic renal failure. Acta Endocrinol 1978; 87:467-75.
37. Blackman MR, Weintraub BD, Kourides IA, et al. Discordant elevation of the common alpha subunit of the pituitary glycoprotein hormones compared to beta subunits in the serum of uremic patients. J Clin Endocrinol Metab 1981; 53:39.
38. Seidell J, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39:897-901.
39. Katznelson L, Rosenthal DI, Rosol MS, et al. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. AJR Am J Roentgenol 1998; 170:423-7.
40. Mauras N, Hayes V, Welch S, et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity. J Clin Endocrinol Metab 1998; 83:1886.
41. Bhasin S, Storer TW, Berman N, et al. A replacement dose of testosterone increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82:407-13.
42. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81:4358-65.
43. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3469-75.
44. Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996; 81:3654-62.
45. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2670-7.
46. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85:2839-53.
47. Morley JE, Perry HMD, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41:149-52.
48. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269:E820-6.
49. Tenover JL. Experience with testosterone replacement in the elderly. Mayo Clin Proc 2000; 75(Suppl):S77-81.
50. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56:M266-72.
51. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281:E1172-81.
52. Mårin P, Odén B, Björntorp P. Assimilation and mobilization of triglycerldes in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80:239-43.
53. Hobbs CJ, Jones RE, Plymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. J Clin Endocrinol Metab 1996; 81:1582-5.
54. Xu XF, De Pergola G, Bjorntorp P. Testosterone increases lipolysls and the number of beta-adrenoceptors in male rat adipocytes. Endocrinology 1991; 128:379-82.
55. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001; 111:261-9.
56. Haffner SM, Laakso M, Miettinen H, Mykkanen L, Karhapaa P, Rainwater DL. Low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men. J Clin Endocrinol Metab 1996; 81:3697-701.
57. De Pergola G, De Mitrio V, Sciaraffia M, et al. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism 1997; 46:1287-93.
58. Bhasin S, Storer TW, Javanbakht M, et al. Effects of testosterone replacement and resistance exercise on muscle strength, and body composition in human immunodeficiency virus-infected men with weight loss and low testosterone levels. JAMA 2000; 283:763-70.
59. Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a non-genital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998; 83:3155-62.
60. Dobs A, Cofrancesco J, Nolten WE, et al. The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 1999; 107:126-32.
61. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129:18-26.
62. Endre T, Mattiasson I, Berglund G, Hulthen UL. Low testosterone and insulin resistance in hypertension-prone men. J Hum Hypertens 1996; 10:755-61.
63. Defay R, Papoz L, Barny S, Bonnot-Lours S, Caces E, Simon D. Hormonal status and NIDDM in the European and Melanesian populations of New Caledonia: a case-control study. The CALedonia DiAbetes Mellitus (CALDIA) Study Group. Int J Obes Relat Metab Disord 1998; 22:927-34.
64. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143:889-97.
65. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma Iipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87:136-43.
66. Holmang A, Bjorntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 1992; 146:505-10.
67. Ng MK, Liu PY, Williams AJ, et al. Prospective study of the effect of androgens on serum inflammatory markers in men. Arterioscler Thromb Vasc Biol 2002; 22:1136-41.
68. Fairfield WP, Treat M, Rosenthal DI, et al. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting. J Appl Physiol 2001; 90:2166.
69. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14:701-6.
70. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 1999; 21:890-4.
71. Stigher LH, Tulgan J. Treatment of angina pectoris by testosterone propionate. N Y State J Med 1943; 43:1424-28.
72. Hamm L. Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol Metab 1942; 2:325-328.
73. Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100:1690-6.
74. Rosano GMC, Leonardo F, Pagnotta P, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 1999; 99:1666-70.
75. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ. Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 2001; 281:H1720-7.
76. Nathan L, Shi W, Dinh H, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci USA 2001; 98:3589-93.